Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
This study is currently recruiting patients.
Sponsored by: | National Eye Institute (NEI) |
---|---|
Information provided by: | Warren G Magnuson Clinical Center (CC) |
Purpose
Vitamin A is an essential nutrient that cannot be made in the body, and it is difficult to get significant amounts of vitamin A from food sources.
The purpose of this study is to determine whether taking an oral vitamin A supplement will improve the retinal function of patients with retinitis pigmentosa (RP). Patients with RP progressively lose the ability to read fine print and perceive color.
Fifteen participants age 18 and older who have various types of RP will participate in this study. They will take vitamin A capsules (doses of 15,000 IU to 50,000 UI) daily for 4 weeks; then they will switch to a lower dose for an additional 2 weeks. At an initial visit to the Clinical Center, participants will undergo a medical history, physical exam, blood work, and an eye exam that includes an electroretinogram. During each of five follow-up visits, doctors will measure the amount of vitamin A in participants' blood to see if it increases over time. The follow-up visits will take place approximately every 2 weeks for approximately 2.5 months.
Condition | Treatment or Intervention | Phase |
---|---|---|
Retinitis Pigmentosa |
Drug: Vitamin A |
Phase I |
MedlinePlus related topics: Eye Diseases; Genetic Disorders; Retinal Disorders
Study Type: Interventional
Study Design: Treatment, Safety
Official Title: Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa
Expected Total Enrollment: 5
Study start: July 17, 2003
Retinitis pigmentosa (RP) is a collective term for a group of inherited retinal dystrophies that are a major cause of irreversible blindness. RP of some type occurs in approximately 1 out of 3500 persons in the United States(1). Gene mutations are responsible for the majority of RP. To date, mutations have been identified in 30 different genes linked to RP(2). The visual prognosis of RP is poor, since the gradual but relentless visual field loss leads eventually to some degree of blindness(3). Although no effective treatment for RP has been identified, participants supplemented with a daily oral dose of 15,000 IU vitamin A palmitate have shown, on average, a slower rate of deterioration of retinal function when the intervention is continued over several years(4). The purpose of this research is to determine whether administration of high oral doses of vitamin A can acutely improve cone photoreceptor function in RP participants as measured by electroretinography (ERG). In this interventional, non-randomized, prospective, pilot study, 5 participants will receive a daily oral dose of 50,000 IU of vitamin A palmitate for 4 weeks, followed by a maintenance dose of 15,000 IU daily for the subsequent 2 weeks. The primary efficacy outcome is a relative percentage change in ERG response amplitude subsequent to vitamin A supplementation. A secondary efficacy outcome is a relative percentage change in implicit time from pre- to post- vitamin A supplementation, with improvement specified as a shorter response implicit time. Other secondary outcomes will be improvements in visual field (Humphery, 10-12; sum of thresholds). Safety outcomes include visual fields, ETDRS visual acuity, intraocular pressure, serum vitamin A level and liver function tests.
Eligibility
Genders Eligible for Study: Both
Criteria
Location and Contact Information
More Information
Publications
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |